These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 31515689)

  • 1. Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barré Syndrome.
    Svačina MKR; Röth P; Bobylev I; Sprenger A; Zhang G; Sheikh KA; Lehmann HC
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):642-648. PubMed ID: 31515689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome.
    Press R; Matá S; Lolli F; Zhu J; Andersson T; Link H
    J Neurol Sci; 2001 Sep; 190(1-2):41-7. PubMed ID: 11574105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antiganglioside autoantibody profiles in Guillain-Barré syndrome].
    Caudie C; Vial C; Bancel J; Petiot P; Antoine JC; Gonnaud PM
    Ann Biol Clin (Paris); 2002; 60(5):589-97. PubMed ID: 12368145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants.
    Koga M; Takahashi M; Yokoyama K; Kanda T
    J Neurol; 2015 Aug; 262(8):1954-60. PubMed ID: 26050638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
    Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
    J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IVIg-induced plasmablasts in patients with Guillain-Barré syndrome.
    Brem MD; Jacobs BC; van Rijs W; Fokkink WJR; Tio-Gillen AP; Walgaard C; van Doorn PA; IJspeert H; van der Burg M; Huizinga R
    Ann Clin Transl Neurol; 2019 Jan; 6(1):129-143. PubMed ID: 30656191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin G subclass distribution of autoantibodies to gangliosides in patients with Guillain-Barre syndrome.
    Ilyas AA; Chen ZW; Cook SD; Mithen FA; Singhal BS
    Res Commun Mol Pathol Pharmacol; 2001 Jul; 109(1-2):115-23. PubMed ID: 11458979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury.
    Zhang G; Massaad CA; Gao T; Pillai L; Bogdanova N; Ghauri S; Sheikh KA
    Exp Neurol; 2016 Aug; 282():49-55. PubMed ID: 27208700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An elderly case of Guillain-Barré syndrome with anti-GT1b antibodies].
    Kinboshi M; Morimoto Y; Yoshida T; Kuzume D; Yamasaki M
    Rinsho Shinkeigaku; 2019 Sep; 59(9):600-603. PubMed ID: 31474642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies.
    Taams NE; Notermans NC; Fokkink WR; Tio-Gillen AP; Huizinga R; Schreurs MWJ; Jacobs BC
    J Peripher Nerv Syst; 2018 Dec; 23(4):227-234. PubMed ID: 30101437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to GM1(NeuGc) in Guillain-Barré syndrome after ganglioside therapy.
    Odaka M; Yuki N; Nobile-Orazio E; Carpo M; Hirata K
    J Neurol Sci; 2000 Apr; 175(2):96-106. PubMed ID: 10831769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyclonal IgM and IgA block in vitro complement deposition mediated by anti-ganglioside antibodies in autoimmune neuropathies.
    Sudo M; Miyaji K; Späth PJ; Morita-Matsumoto K; Yamaguchi Y; Yuki N
    Int Immunopharmacol; 2016 Nov; 40():11-15. PubMed ID: 27567246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
    Kuwahara M; Suzuki S; Takada K; Kusunoki S
    J Neuroimmunol; 2011 Oct; 239(1-2):87-90. PubMed ID: 21914557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Streptococcal IdeS: therapeutic potential for Guillain-Barré syndrome.
    Takahashi R; Yuki N
    Sci Rep; 2015 Jul; 5():10809. PubMed ID: 26194472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of anti-ganglioside antibodies in Guillain-Barré syndrome and its variants by the agglutination assay.
    Alaedini A; Briani C; Wirguin I; Siciliano G; D'Avino C; Latov N
    J Neurol Sci; 2002 Apr; 196(1-2):41-4. PubMed ID: 11959155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of immunoblotting and ELISA for detection of anti-ganglioside antibodies in children with Guillain-Barre syndrome.
    Bonyadi MR; Barzegar M; Badalzadeh R; Hashemilar M
    Iran J Immunol; 2010 Jun; 7(2):117-23. PubMed ID: 20574125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
    J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ataxic Guillain-Barré syndrome associated with anti-GM1b and anti-GalNAc-GD1a antibodies.
    Odaka M; Yuki N; Tatsumoto M; Tateno M; Hirata K
    J Neurol; 2004 Jan; 251(1):24-9. PubMed ID: 14999485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GD1b-specific antibody induces ataxia in Guillain-Barre syndrome.
    Kaida K; Kamakura K; Ogawa G; Ueda M; Motoyoshi K; Arita M; Kusunoki S
    Neurology; 2008 Jul; 71(3):196-201. PubMed ID: 18625966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.